AzTrials
AzTrials

Spinal AnesthesiaPhase 4NCT02369510

Does the Addition of Epinephrine Prolong the Duration of Spinal Anesthesia for Repeat Cesarean Section?

A Phase 4 study testing Low-dose epinephrine, High-dose epinephrine and No epinephrine in people with Spinal Anesthesia and Cesarean Section, run by Icahn School of Medicine at Mount Sinai at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study is to investigate whether the addition of a medication called epinephrine to spinal medications prolongs the duration of the anesthesia. The medication standardly used in spinal anesthesia is a local anesthetic (bupivacaine) and an opiate pain medication (morphine). Read more about this study

Who is it for?
Ages 18 to 50 years, women onlyHealthy volunteers can take part
Conditions the study is for
Spinal Anesthesia, Cesarean Section
What is being tested?
Low-dose epinephrine, High-dose epinephrine and No epinephrine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
68 participants
Where
1 siteUnited States
Study dates
Feb 2015to May 2016
Phase
Phase 4
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 50 years
  • Women only
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Non-emergent repeat cesarean section
  • Neuraxial anesthesia as the planned primary anesthetic
  • Informed consent obtained
  • Females age 18-50

Who cannot join

  • Emergency cesarean section
  • Anesthetic other than neuraxial
  • Allergy to local anesthetics, morphine, or epinephrine
  • Pre-existing sensory/motor deficit

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Icahn School of Medicine at Mount Sinai

    New York, New York, 10029

Other trials in United States

About this study

Official title: Does the Addition of Epinephrine Increase the Duration of Intrathecal Hyperbaric Bupivacaine for Repeat Cesarean Section?

The purpose of this study is to investigate whether the addition of a medication called epinephrine to spinal medications prolongs the duration of the anesthesia. The medication standardly used in spinal anesthesia is a local anesthetic (bupivacaine) and an opiate pain medication (morphine). These medications typically last about 2 hours. The investigators want to determine if adding epinephrine to the spinal medications prolongs the anesthetic without side effects. A longer duration of anesthesia may be useful in prolonged repeat cesarean section. Epinephrine is known to prolong the action of some local anesthetics, but the investigators want to specifically study combining it with the medications the investigators use regularly for cesarean section.

You may qualify to take part in this research study because you are having a repeat cesarean section. Repeat cesarean sections sometimes last longer than 2 hours. The investigators want to determine if epinephrine will prolong the anesthetic.

Read the detailed description

Spinal anesthesia with bupivacaine is a commonly used anesthetic in the obstetric population. It is most frequently carried out as a single shot intrathecal injection. This method can be utilized for both labor analgesia and surgical anesthesia for cesarean section. One of the concerns in using a single shot spinal injection for surgical anesthesia is the duration of adequate surgical conditions. This concern is especially relevant to repeat cesarean sections, as each subsequent procedure has the potential to be more complex than the prior and, therefore, prolonged. A reliable way to prolong surgical anesthesia provided by single shot spinal injection of bupivacaine could prove invaluable in the setting of repeat cesarean section. It has been well documented that adding epinephrine to intrathecal lidocaine will increase its duration1, but the evidence for augmenting the duration of anesthesia provided by adding epinephrine to bupivacaine is much more equivocal and less robust. This is a randomized control trial investigating whether or not adding epinephrine to a standard single intrathecal injection of hyperbaric bupivacaine for repeat cesarean will prolong its duration. It will be investigated using women who are undergoing scheduled repeat cesarean section in whom neuraxial anesthesia is the appropriate primary anesthetic. The investigators will compare the onset, quality and duration of both sensory and motor components of the spinal block as well as the incidence of known side effects.

Being tested
Low-dose epinephrine, High-dose epinephrine, No epinephrine
Keywords
spinal anesthesia, epinephrine, bupivacaine, repeat cesarean

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Low-dose epinephrineDrug

    0.1ml of preservative-free saline and 0.1ml of 1:1000 epinephrine will be added to the standard spinal medications

  • High-dose epinephrineDrug

    Also called adrenaline

    0.2ml of 1:1000 epinephrine will be added to the standard spinal medications

  • No epinephrineDrug

    Also called preservative-free saline

    0.2ml of preservative-free saline will be added to the standard spinal medications

Study groups in NCT02369510
Study groupRoleWhat they receive
Low-dose epinephrineExperimental100micrograms of epinephrine group
Receives: Drug: Low-dose epinephrine
High-dose epinephrineExperimental200micrograms of epinephrine group
Receives: Drug: High-dose epinephrine
No epinephrinePlacebo comparator0.2ml saline
Receives: Drug: No epinephrine

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Sensory Recovery

    Time to T10 sensory recovery as measured by pinprick sensation

    Measured: up to 3 hours

Secondary outcomes (7)
  1. Motor Recovery

    Time to Bromage 3 motor recovery

    Measured: up to 4 hours

  2. Block Onset

    Time to a onset of T4 level of anesthesia or the highest level achieved in 15min

    Measured: up to 15 min

  3. Number of Participants With Hypotension

    Incidence of hypotension as measured by participants needing vasopressor agents

    Measured: at 2 minutes and at 25 minutes

  4. Adequacy of Anesthesia

    As measured by pinprick sensation and/or patient discomfort as measured by verbal pain score on a scale of 0=no pain to 10=worst imaginable pain, obtained within 3 hours of receiving anesthesia.

    Measured: up to 3 hrs

  5. Patient Satisfaction

    Patient satisfaction score was elicited upon arrival to the recovery room on a 1-5 Likert scale. Number of participants selecting the highest score of 5 or "completely satisfied".

    Measured: up to 3 hours

  6. Incidence of Nausea and Vomiting

    Measured: up to 3 hours

  7. Incidence of Pruritus

    data not collected

    Measured: up to 3 hours

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 Feb 2015 (estimated)
  2. Study startFeb 2015
  3. Primary completionMay 2016
  4. Study completionMay 2016

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Supportive care
Allocation
Randomised
Intervention model
Parallel groups
Masking
Triple blind
Who is masked
Participant, Care provider, Investigator
Enrolment
68 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02369510
Sponsor's protocol ID
GCO 14-2058
Status last verified
Aug 2017
First submitted
17 Feb 2015
Last updated
30 Aug 2017
Data monitoring committee
No

Publications

  • Katz D, Hamburger J, Gutman D, Wang R, Lin HM, Marotta M, Zahn J, Beilin Y. The Effect of Adding Subarachnoid Epinephrine to Hyperbaric Bupivacaine and Morphine for Repeat Cesarean Delivery: A Double-Blind Prospective Randomized Control Trial. Anesth Analg. 2018 Jul;127(1):171-178. doi: 10.1213/ANE.0000000000002542.

    PubMed 29077615

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Low-dose epinephrine, High-dose epinephrine and No epinephrine in people with Spinal Anesthesia and Cesarean Section, run by Icahn School of Medicine at Mount Sinai at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 30 Aug 2017. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 30 Aug 2017). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Sensory Recovery (time frame: up to 3 hours). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02369510, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Aug 2017.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in